---
figid: PMC5570578__gr7
figtitle: Illustration describing the role of HPV E6/E7 oncogenes and HPV E6/E7 siRNA
  with cisplatin (CDDP) plus paclitaxel (PTX) therapy on HPV-infected cervical cancer
  cell fates
organisms:
- NA
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC5570578
filename: gr7.jpg
figlink: /pmc/articles/PMC5570578/figure/f0035/
number: F7
caption: Illustration describing the role of HPV E6/E7 oncogenes and HPV E6/E7 siRNA
  with cisplatin (CDDP) plus paclitaxel (PTX) therapy on HPV-infected cervical cancer
  cell fates. HPV-E6 and E7 bind to TP53 and RB (tumor suppressors proteins) and degrade
  the protein, respectively, leading to repression of p21 (p21WAF1/Cip1) and facilitating
  free E2Fs through the activation of cyclin/CDK complexes. As a result of triple
  combination therapy, inactivation of TP53 and RB/E2F pathway is prevented, and TP53,
  p21, and hypophosphorylated RB (pRB) protein level increases. Overall, high level
  of TP53 results in cell cycle arrest and cell proliferation inhibition. Arrows indicate
  a positive effect, while flat lines indicate inhibition.
papertitle: Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation
  of TP53/E2F Dynamic Behavior for Cell Fate Decisions.
reftext: Nirmal Rajasekaran, et al. Neoplasia. 2017 Oct;19(10):735-749.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9272068
figid_alias: PMC5570578__F7
figtype: Figure
redirect_from: /figures/PMC5570578__F7
ndex: 5eeeeed4-df0c-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5570578__gr7.html
  '@type': Dataset
  description: Illustration describing the role of HPV E6/E7 oncogenes and HPV E6/E7
    siRNA with cisplatin (CDDP) plus paclitaxel (PTX) therapy on HPV-infected cervical
    cancer cell fates. HPV-E6 and E7 bind to TP53 and RB (tumor suppressors proteins)
    and degrade the protein, respectively, leading to repression of p21 (p21WAF1/Cip1)
    and facilitating free E2Fs through the activation of cyclin/CDK complexes. As
    a result of triple combination therapy, inactivation of TP53 and RB/E2F pathway
    is prevented, and TP53, p21, and hypophosphorylated RB (pRB) protein level increases.
    Overall, high level of TP53 results in cell cycle arrest and cell proliferation
    inhibition. Arrows indicate a positive effect, while flat lines indicate inhibition.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TP53
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - ATP8A2
  - CCNE1
  - CCNE2
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDK2
  - RB1
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - ATM
  - CHEK1
  - CHEK2
  - tp53
  - cdkn1a
  - cdk2
  - atr
  - atm
  - Cisplatin
  - Paclitaxel
---
